Activation AMPK in Hypothalamic Paraventricular Nucleus Improves Renovascular Hypertension Through ERK1/2-NF-κB Pathway

Cardiovasc Toxicol. 2024 Sep;24(9):904-917. doi: 10.1007/s12012-024-09888-9. Epub 2024 Jul 15.

Abstract

Hypertension is a globally prevalent disease, but the pathogenesis remains largely unclear. AMP-activated protein kinase (AMPK) is a nutrition-sensitive signal of cellular energy metabolism, which has a certain influence on the development of hypertension. Previously, we found a down-regulation of the phosphorylated (p-) form of AMPK, and the up-regulation of the angiotensin II type 1 receptor (AT1-R) and that of p-ERK1/2 in the hypothalamic paraventricular nucleus (PVN) of hypertensive rats. However, the exact mechanism underlying the relationship between AMPK and AT1-R in the PVN during hypertension remains unclear. Thus, we hypothesized that AMPK modulates AT1-R through the ERK1/2-NF-κB pathway in the PVN, thereby inhibiting sympathetic nerve activity and improving hypertension. To examine this hypothesis, we employed a renovascular hypertensive animal model developed via two-kidney, one-clip (2K1C) and sham-operated (SHAM). Artificial cerebrospinal fluid (aCSF), used as vehicle, or 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR, an AMPK activator, 60 μg/day) was microinjected bilaterally in the PVN of these rats for 4 weeks. In 2K1C rats, there an increase in systolic blood pressure (SBP) and circulating norepinephrine (NE). Also, the hypertensive rats had lowered expression of p-AMPK and p-AMPK/AMPK, elevated expression of p-ERK1/2, p-ERK1/2/ERK1/2 and AT1-R, increased NF-κB p65 activity in the PVN compared with the levels of these biomarkers in SHAM rats. Four weeks of bilateral PVN injection of AMPK activator AICAR, attenuated the NE level and SBP, increased the expression of p-AMPK and p-AMPK/AMPK, lessened the NF-κB p65 activity, decreased the expression of p-ERK1/2, p-ERK1/2/ERK1/2 and AT1-R in the PVN of 2K1C rats. Data from this study imply that the activation of AMPK within the PVN suppressed AT1-R expression through inhibiting the ERK1/2-NF-κB pathway, decreased the activity of the sympathetic nervous system, improved hypertension.

Keywords: AMP-activated protein kinase; AT1-R; ERK1/2; Hypertension; Hypothalamic paraventricular nucleus.

MeSH terms

  • AMP-Activated Protein Kinases* / metabolism
  • Aminoimidazole Carboxamide / analogs & derivatives
  • Aminoimidazole Carboxamide / pharmacology
  • Animals
  • Antihypertensive Agents / pharmacology
  • Disease Models, Animal*
  • Enzyme Activation*
  • Hypertension, Renovascular* / drug therapy
  • Hypertension, Renovascular* / enzymology
  • Hypertension, Renovascular* / metabolism
  • Hypertension, Renovascular* / physiopathology
  • Male
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3* / metabolism
  • NF-kappa B / metabolism
  • Paraventricular Hypothalamic Nucleus* / drug effects
  • Paraventricular Hypothalamic Nucleus* / enzymology
  • Paraventricular Hypothalamic Nucleus* / metabolism
  • Paraventricular Hypothalamic Nucleus* / physiopathology
  • Phosphorylation
  • Rats
  • Rats, Sprague-Dawley*
  • Receptor, Angiotensin, Type 1* / metabolism
  • Ribonucleotides / pharmacology
  • Signal Transduction
  • Sympathetic Nervous System / drug effects
  • Sympathetic Nervous System / metabolism
  • Sympathetic Nervous System / physiopathology
  • Transcription Factor RelA / metabolism

Substances

  • AMP-Activated Protein Kinases
  • Mapk1 protein, rat
  • Receptor, Angiotensin, Type 1
  • Mitogen-Activated Protein Kinase 3
  • Transcription Factor RelA
  • Ribonucleotides
  • AICA ribonucleotide
  • Mitogen-Activated Protein Kinase 1
  • Aminoimidazole Carboxamide
  • Rela protein, rat
  • NF-kappa B
  • Antihypertensive Agents